Skip to main content
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRDA ISIN · US29384C1080 US Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2023-04-04 Director's Dealing
Country US United States of America
Listing US TRDA

About Entrada Therapeutics, Inc.

https://www.entradatx.com/

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of medicines to treat devastating diseases. The company's proprietary Endosomal Escape Vehicle (EEV) platform is designed to enable the intracellular delivery of a wide range of therapeutics, allowing access to targets that have historically been considered undruggable. Entrada's development pipeline is concentrated on rare conditions, with programs targeting neuromuscular diseases, including Duchenne muscular dystrophy, as well as ocular diseases. The company's mission is to transform the lives of patients by establishing EEV-based therapeutics as a new treatment modality.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2023-04-04 English
FORM 3
Director's Dealing
2023-04-04 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is the appointment of a new director to the Board of Directors, including details about the director's compensation and committee assignments. There is no financial data or comprehensive report content. The primary focus is on changes in the company's board composition and management. Therefore, this filing fits the category of Board/Management Information (MANG). The document length (6080 characters) supports it being a full filing rather than a brief announcement or certification. Hence, the classification is MANG with high confidence.
2023-04-04 English
FORM 4
Director's Dealing
2023-03-29 English
FORM S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Entrada Therapeutics, Inc. It registers additional shares of common stock under the company's 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan. The document includes details about the plans, share increases, and exhibits related to corporate governance documents and legal opinions. Form S-8 is specifically used for registering securities to be offered under employee benefit plans, which is a capital raising activity related to stock issuance. This fits the category of Share Issue/Capital Change (SHA) rather than a financial report or other filing type. The document length is 9577 characters, indicating it is a full registration statement, not a brief announcement or certification. Therefore, the correct classification is SHA with high confidence.
2023-03-06 English
10-K
Annual Report FY 2022
2023-03-06 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.